433 related articles for article (PubMed ID: 31502008)
1. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
2. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
3. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
4. Challenges of cancer therapy with natural killer cells.
Klingemann H
Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
6. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
7. NK cell-based cancer immunotherapy: from basic biology to clinical application.
Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
11. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
12. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
[TBL] [Abstract][Full Text] [Related]
13. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
14. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
[TBL] [Abstract][Full Text] [Related]
15. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
17. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
18. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
